Literature DB >> 18949369

Protein kinase A serves as a primary pathway in activation of Nur77 expression by gonadotropin-releasing hormone in the LbetaT2 mouse pituitary gonadotroph tumor cell line.

Tariq Hamid1, Mohammed T Malik, Robert P Millar, Sham S Kakar.   

Abstract

Nur77 belongs to a subfamily of nuclear receptors that includes two other members, Nor-1 and Nurr1. It plays an important role in a number of biological processes, including regulation of signaling functions in the hypothalamo-pituitary-adrenal axis, regulation of thymocyte apoptosis, regulation of steroidogenesis and regulation of tumor cell proliferation and apoptosis. In previous studies, using DNA microarray analysis of the effects of the gonadotropin-releasing hormone (GnRH) on the mouse pituitary gonadotroph cell line LbetaT2, we identified Nur77 as one of the highly regulated immediate early genes involved in this response, with >40-fold upregulation after 1 h of treatment of the cells with the GnRH agonist [D-Ala6GnRH (GnRHA)]. GnRH is a hypothalamic decapeptide that stimulates the secretion and expression of gonadotropins (follicle stimulating hormone, FSH and luteinizing hormone releasing hormone, LH) from anterior pituitary through activation of high affinity receptors present on cell membrane of pituitary gonadotropes. In addition to pituitary, the presence of GnRH high affinity receptors has been reported in various cancers and cancer cell lines. In addition, GnRH and its analogs are clinically used in the treatment of prostate cancer. To elucidate the molecular mechanism involved in regulation of Nur77 by GnRH, we first confirmed upregulation of Nur77 in response to GnRH analog (GnRHA) in LbetaT2 cells. Nur77 mRNA was upregulated within 30 min of GnRHA treatment and returned to nearly basal level after 24 h of treatment. Nur77 protein expression was upregulated after 2 h of treatment and remained steady even after 12 h of treatment. The expression of Nur77 mRNA was induced by GnRHA in a dose-dependent manner. Induction of Nur77 expression was stimulated on treatment of cells with forskolin and 8-Br-cAMP, whereas H-89, a specific inhibitor of PKA pathway significantly inhibited GnRHA-induced Nur77 expression. Treatment of cells with both H-89 and EGTA completely blocked the GnRHA-induced expression of Nur77, indicating that both calcium and cAMP/PKA play an important role in regulation of Nur77 expression by GnRHA. Analysis of the protein kinase C (PKC) signaling pathway using specific inhibitors for PKC, Erk1/2, p38 and JNK demonstrated that these pathways are not involved in GnRHA-induced Nur77 expression. Based on our results, we conclude that activation of protein kinase A is the major mechanism regulating the expression of Nur77 by GnRH which may serve as a down-stream signaling gene to mediate the antitumor effects of GnRH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949369

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

Review 1.  GnRH-A Key Regulator of FSH.

Authors:  George A Stamatiades; Rona S Carroll; Ursula B Kaiser
Journal:  Endocrinology       Date:  2019-01-01       Impact factor: 4.736

2.  PPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice.

Authors:  Shweta Sharma; Prem M Sharma; Devendra S Mistry; R Jeffery Chang; Jerrold M Olefsky; Pamela L Mellon; Nicholas J G Webster
Journal:  Biol Reprod       Date:  2010-11-10       Impact factor: 4.285

3.  Calcineurin mediates the gonadotropin-releasing hormone effect on expression of both subunits of the follicle-stimulating hormone through distinct mechanisms.

Authors:  Lilach Pnueli; Min Luo; Sihui Wang; Zvi Naor; Philippa Melamed
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

4.  ERK signaling, but not c-Raf, is required for gonadotropin-releasing hormone (GnRH)-induced regulation of Nur77 in pituitary gonadotropes.

Authors:  Stuart P Bliss; Amy M Navratil; Jianjun Xie; Andrew Miller; Manuela Baccarini; Mark S Roberson
Journal:  Endocrinology       Date:  2011-12-20       Impact factor: 4.736

5.  SET protein interacts with intracellular domains of the gonadotropin-releasing hormone receptor and differentially regulates receptor signaling to cAMP and calcium in gonadotrope cells.

Authors:  Charlotte Avet; Ghislaine Garrel; Chantal Denoyelle; Jean-Noël Laverrière; Raymond Counis; Joëlle Cohen-Tannoudji; Violaine Simon
Journal:  J Biol Chem       Date:  2012-12-11       Impact factor: 5.157

6.  Chronic methamphetamine exposure suppresses the striatal expression of members of multiple families of immediate early genes (IEGs) in the rat: normalization by an acute methamphetamine injection.

Authors:  Michael T McCoy; Subramaniam Jayanthi; Jacqueline A Wulu; Genevieve Beauvais; Bruce Ladenheim; Tracey A Martin; Irina N Krasnova; Amber B Hodges; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2011-01-13       Impact factor: 4.530

7.  TGFβ-Induced Lung Cancer Cell Migration Is NR4A1-Dependent.

Authors:  Erik Hedrick; Kumaravel Mohankumar; Stephen Safe
Journal:  Mol Cancer Res       Date:  2018-08-02       Impact factor: 5.852

8.  NGFI-B targets mitochondria and induces cardiomyocyte apoptosis in restraint-stressed rats by mediating energy metabolism disorder.

Authors:  XinXing Wang; XiaoHua Liu; RuiRui Kong; Rui Zhan; XiaoMing Wang; Xue Leng; JingBo Gong; Meng Duan; LiQun Wang; Lei Wu; LingJia Qian
Journal:  Cell Stress Chaperones       Date:  2009-05-03       Impact factor: 3.667

9.  Relevance of the NR4A sub-family of nuclear orphan receptors in trophoblastic BeWo cell differentiation.

Authors:  Sudha Saryu Malhotra; Satish Kumar Gupta
Journal:  Cell Mol Biol Lett       Date:  2017-08-09       Impact factor: 5.787

10.  Decoding high Gonadotropin-releasing hormone pulsatility: a role for GnRH receptor coupling to the cAMP pathway?

Authors:  Joëlle Cohen-Tannoudji; Charlotte Avet; Ghislaine Garrel; Raymond Counis; Violaine Simon
Journal:  Front Endocrinol (Lausanne)       Date:  2012-08-31       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.